PBYI Q1 2020 Earnings — Puma Biotechnology, Inc. Revenue & Financial Results | Market Cap Arena

PBYIPuma Biotechnology, Inc.

$299M

Q1 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$51M-48.3% YoY

Gross Profit

$42M82.3% margin

Operating Income

-$14M-27.8% margin

Net Income

-$17M-33.1% margin

EPS (Diluted)

$-0.43

QoQ Revenue Growth

-18.6%

Cash Flow

Operating Cash Flow

-$12M

Free Cash Flow

-$12M

Stock-Based Comp.

$9M

Balance Sheet

Total Assets

$226M

Total Liabilities

$216M

Stockholders' Equity

$9M

Cash & Equivalents

$83M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$51M	$99M	-48.3%
Gross Profit	$42M	$91M	-53.7%
Operating Income	-$14M	-$10M	-41.3%
Net Income	-$17M	-$10M	-67.7%

Revenue Segments

Product

$49M95%

License

$2M4%

Royalty

$608,0001%